Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent - Darapladib


The goal of the trial was to evaluate darapladib, a selective lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), on biomarkers of cardiovascular risk in patients with stable coronary heart disease.